CARA News and Press, Cara Therapeutics Inc. From 04/06/21

Shares of Cara Therapeutics (NASDAQ: CARA) were soaring 13.1% higher as of 10:45 a.m. EDT on Tuesday. The big gain came after S&P Global division S&P Dow Jones Indices announced that Cara will replace MTS Systems in the S&P SmallCap 600 index . The nice j...

Brooklyn Immuno Therapeutics (BTX) +77%.Scienjoy Holding (SJ) +37% on strategic alliance with Snipp.Weidai (WEI) +26%.Elite Education Group International (EEIQ) +16%.Phunware (PHUN) +12%. as board authorizes bitcoin purchases for Blockchain Ecosystem Launch.Romeo Power (RMO) +12% as...

Cara Therapeutics Set to Join S&P SmallCap 600 Cara Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , April 5, 2021 /PRNewswire/ -- Cara Therapeutics Inc. (NASD:CARA) will replace MTS Systems Corp. (NASD:MTSC) in the S&P SmallCap 60...

Gainers: [[CARA]] +10.5%. [[ILMN]] +10.4%. [[TMDX]] +6.0%. [[NTES]] +5.5%. [[HPK]] +4.7%.Losers: [[MDB]] -8.3%. [[RNA]] -7.4%. [[UCTT]] -6.9%. [[XELB]] -5.0%. [[PYPL]] -4.6%. For further details see: CARA, ILMN, MDB and RNA among after-hours movers

Cara Therapeutics (CARA) is up 20.9% after hours following news it's joining the S&P SmallCap 600 index. It's there to replace MTS Systems (MTSC), which is set to be acquired by Amphenol. The index move is effective prior to the open of trading Thursday, April 8. For further details see...

STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today a...

Cara Therapeutics (CARA) and Vifor Fresenius Medical Care Renal Pharma (GNHAF) announce that the EMA has accepted to review the Marketing Authorization Application ((MAA)) for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis pat...

Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the first therapy available in Europe for treatment of pruritus associated with chronic kidney disease in hemodialysis...

Under Priority review, the FDA has accepted Cara Therapeutics (CARA) and Vifor Pharma's (GNHAF) New Drug Application ((NDA)) for Korsuva (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.The PDUFA target action date is August 23, ...

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE ...